194 related articles for article (PubMed ID: 16906549)
1. Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.
Page PZ; Page GP; Ecosse E; Korf BR; Leplege A; Wolkenstein P
Am J Med Genet A; 2006 Sep; 140(18):1893-8. PubMed ID: 16906549
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases.
Wolkenstein P; Zeller J; Revuz J; Ecosse E; Leplège A
Arch Dermatol; 2001 Nov; 137(11):1421-5. PubMed ID: 11708944
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients.
Kodra Y; Giustini S; Divona L; Porciello R; Calvieri S; Wolkenstein P; Taruscio D
Dermatology; 2009; 218(3):215-20. PubMed ID: 19088462
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1.
Hamoy-Jimenez G; Elahmar HA; Mendoza M; Kim RH; Bril V; Barnett C
Orphanet J Rare Dis; 2022 Feb; 17(1):40. PubMed ID: 35135568
[TBL] [Abstract][Full Text] [Related]
5. Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.
Wolkenstein P; Rodriguez D; Ferkal S; Gravier H; Buret V; Algans N; Simeoni MC; Bastuji-Garin S
Br J Dermatol; 2009 Apr; 160(4):844-8. PubMed ID: 19067713
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.
Ferner RE; Thomas M; Mercer G; Williams V; Leschziner GD; Afridi SK; Golding JF
Health Qual Life Outcomes; 2017 Feb; 15(1):34. PubMed ID: 28193237
[TBL] [Abstract][Full Text] [Related]
7. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement.
Bottesi G; Spoto A; Trevisson E; Zuccarello D; Vidotto G; Cassina M; Clementi M
Br J Dermatol; 2020 Jun; 182(6):1449-1457. PubMed ID: 31329288
[TBL] [Abstract][Full Text] [Related]
8. Association of sociodemographic and clinical factors with the quality of life of Brazilian individuals with Neurofibromatosis type 1: a cross-sectional study.
Bicudo NP; Germano CMR; de Moraes RT; de Avó LRDS; Ferner RE; Melo DG
An Bras Dermatol; 2024; 99(4):520-526. PubMed ID: 38493052
[TBL] [Abstract][Full Text] [Related]
9. Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1.
Cieza Rivera AM; Lobato Fuertes C; Fernández-Villa T; Martín Sánchez V; Atallah I
Orphanet J Rare Dis; 2024 Feb; 19(1):85. PubMed ID: 38402381
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior.
Krab LC; Oostenbrink R; de Goede-Bolder A; Aarsen FK; Elgersma Y; Moll HA
J Pediatr; 2009 Mar; 154(3):420-5, 425.e1. PubMed ID: 18950800
[TBL] [Abstract][Full Text] [Related]
11. Characterization of health concerns in people with neurofibromatosis type 1.
Fleming J; Morgan O; Wong C; Schlub TE; Berman Y
Mol Genet Genomic Med; 2023 Jan; 11(1):e2077. PubMed ID: 36444392
[TBL] [Abstract][Full Text] [Related]
12. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
Bernier A; Larbrisseau A; Perreault S
Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
[TBL] [Abstract][Full Text] [Related]
13. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
14. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
15. Analysis of neurofibromatosis 1 (NF1) lesions by body segment.
Palmer C; Szudek J; Joe H; Riccardi VM; Friedman JM
Am J Med Genet A; 2004 Mar; 125A(2):157-61. PubMed ID: 14981716
[TBL] [Abstract][Full Text] [Related]
16. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.
Cohen JS; Levy HP; Sloan J; Dariotis J; Biesecker BB
Clin Genet; 2015 Nov; 88(5):425-30. PubMed ID: 25534182
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Factors of Quality of Life Among Patients With Neurofibromatosis Type 1-Associated Craniofacial Plexiform Neurofibromas.
Ren JY; Gu YH; Wei CJ; Huang X; Xu XW; Gu B; Zan T; Wang ZC; Li QF
J Craniofac Surg; 2020; 31(2):347-350. PubMed ID: 31977693
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with anogenital warts.
Paradisi A; Capizzi R; Ricci F; Di Pietro C; Abeni D; Tabolli S
Eur J Dermatol; 2013; 23(6):837-42. PubMed ID: 24192222
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1.
Graf A; Landolt MA; Mori AC; Boltshauser E
J Pediatr; 2006 Sep; 149(3):348-53. PubMed ID: 16939745
[TBL] [Abstract][Full Text] [Related]
20. An Update on Neurofibromatosis Type 1: Not Just Café-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer.
Hernández-Martín A; Duat-Rodríguez A
Actas Dermosifiliogr; 2016; 107(6):465-73. PubMed ID: 26956402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
